Research Advance on Teatment of Second Primary Malignancy in Patients with Multiple Myeloma / 中国实验血液学杂志

ABSTRACT

Multiple myeloma (MM) is a neoplastic plasma-cell disorder that characterized by clonal proliferation of malignant plasma cells in the bone marrow microenvironment, monoclonal protein in the blood or urine, and associated organ dysfunction. Survival of patients with MM has improved dramatically since the introduction of stem-cell transplantation and new agents. Indeed, multiple myeloma has seen more remarkable progress in treatment and outcome patients than any other cancer in the last decade. With improvements in survival, a relatively new clinical challenge that has emerged is the risk of second primary malignancies, which does not only increase the difficulty of treatment, but also have a bad influence on the overall survival rate of patients, so second primary malignancy of MM has become a new clinical challenges in MM treatment. In this review, the latest progress of studies on treatment related factors, MM self factors and host self factots are summarized.